June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Corneal Crosslinking to Regress Pathological Corneal Neovascularization Before High-Risk Keratoplasty
Author Affiliations & Notes
  • Deniz Hos
    Universitat zu Koln, Koln, Nordrhein-Westfalen, Germany
  • Friederike Schaub
    Universitat zu Koln, Koln, Nordrhein-Westfalen, Germany
  • Yanhong Hou
    Universitat zu Koln, Koln, Nordrhein-Westfalen, Germany
  • Wei Zhang
    Universitat zu Koln, Koln, Nordrhein-Westfalen, Germany
  • Felix Bock
    Universitat zu Koln, Koln, Nordrhein-Westfalen, Germany
  • Claus Cursiefen
    Universitat zu Koln, Koln, Nordrhein-Westfalen, Germany
  • Footnotes
    Commercial Relationships   Deniz Hos, None; Friederike Schaub, None; Yanhong Hou, None; Wei Zhang, None; Felix Bock, None; Claus Cursiefen, None
  • Footnotes
    Support  German Research Foundation (DFG) FOR2240; Center for Molecular Medicine Cologne, University of Cologne
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 974. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Deniz Hos, Friederike Schaub, Yanhong Hou, Wei Zhang, Felix Bock, Claus Cursiefen; Corneal Crosslinking to Regress Pathological Corneal Neovascularization Before High-Risk Keratoplasty. Invest. Ophthalmol. Vis. Sci. 2021;62(8):974.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal neovascularization is the main risk factor for graft rejection after high-risk penetrating keratoplasty (PK). Corneal crosslinking (CXL) has been shown to regress pathological corneal neovascularization and to reduce the risk of graft rejection after high-risk PK in mice. The aim of this work was to analyze whether CXL of the corneal periphery sparing the limbus ("peripheral CXL") is also able to regress corneal neovascularization in patients.

Methods : This case series included 5 patients with progressive corneal neovascularization and the need for high-risk PK because of graft rejection and/or keratitis. Peripheral CXL was performed prior to or directly in combination with PK, and corneal neovascularization was assessed morphometrically on slit-lamp images. Patients were followed up to determine the incidence of adverse effects and graft rejection.

Results : No intraoperative or postoperative complications were observed. Peripheral CXL resulted in a significant reduction of corneal neovascularization (mean reduction of 70.5% ± 22.7%). Revascularization was not observed. All transplants remained clear and without immune reactions (mean follow-up 16.4 ± 14.9 weeks, range 4-42 weeks).

Conclusions : Peripheral CXL is able to reduce pathological corneal neovascularization in patients and might therefore be a novel treatment option to reduce graft rejection rates after high-risk PK.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×